- Source: Philip Felgner
Philip Louis Felgner (born 7 February 1950) is an American biochemists and immunologists, specialized in lipofection technology and genetics. He is one of the developers of the vaccine against the SARS-CoV-2 virus, responsible for COVID-19 pandemic. He is currently the director of the UCI Vaccine Research & Development Center as well as the Protein Microarray Laboratory and Training Facility.
In 1972, he graduated in biochemistry from the Michigan State University, earning his master's degree in 1975 and his Ph.D. in 1978. He did postdoctoral work at the University of Virginia.
In 2021, he was awarded the Princess of Asturias Awards for Technical and Scientific Research along Katalin Karikó, Drew Weissman, Uğur Şahin, Özlem Türeci, Derrick Rossi, and Sarah Gilbert.
In 2022, Philip Felgner was awarded the Robert Koch Prize, one of the stepping-stones to eventual Nobel Prize recognition for scientists in the fields of microbiology and immunology, for his fundamental contributions to the development of lipofection technology, a technology widely used in basic research in medicine for introducing active substances into cells and also the basis of modern mRNA vaccines.
In 2022, Philip Felgner was named Fellow by National Academy of Inventors. As of 2022, he has published 280 papers that have been cited 44,000 times and has 53 U.S. patents and 56 foreign patents, including 14 licensed patents.
In 2023, the pioneering work of synthesizing the first cationic lipid (DOTMA) (lipofectin) for DNA and RNA delivery into cells by Philip Felgner was mentioned in the advanced scientific information posted by the Nobel Prize committee for the Nobel Prize in Physiology or Medicine in 2023.
References
Kata Kunci Pencarian:
- Philip Felgner
- Felgner
- Robert W. Malone
- Derrick Rossi
- Yann LeCun
- Joanne Chory
- Jens Juul Holst
- Drew Weissman
- Svetlana Mojsov
- Sarah Gilbert
